Open AccessNeoadjuvant treatment strategy for locally advanced thoracic esophageal cancer
Author(s) -
Mayanagi Shuhei,
Irino Tomoyuki,
Kawakubo Hirofumi,
Kitagawa Yuko
Publication year - 2019
Publication title -
annals of gastroenterological surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.308
H-Index - 15
ISSN - 2475-0328
DOI - 10.1002/ags3.12243
Subject(s) - medicine , regimen , carboplatin , esophageal cancer , docetaxel , chemoradiotherapy , radiation therapy , neoadjuvant therapy , esophagectomy , cisplatin , lymphadenectomy , oncology , chemotherapy , surgery , cancer , breast cancer
Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer. Based on the results of the Japan Clinical Oncology Group 9907 (JCOG9907) trial, neoadjuvant chemotherapy, two courses of cisplatin and 5‐fluorouracil (5‐ FU ), followed by esophagectomy with D2 lymphadenectomy is the recommended treatment in Japan. Alternatively, neoadjuvant chemoradiotherapy ( NACRT ) typified by carboplatin and paclitaxel plus concurrent radiotherapy with 41.4 Gy (Chemoradiotherapy for Esophageal Cancer followed by Surgery Study [CROSS]) has shown promising outcomes in some Western countries. Currently, several clinical trials are being conducted within and outside of Japan to confirm the best neoadjuvant treatment regimen. For instance, a three‐arm phase III randomized controlled trial ( JCOG 1109) is ongoing in Japan. The three arms comprise a doublet regimen (two courses of cisplatin 80 mg/m 2 day 1 and 5‐ FU 800 mg/m 2 days 1‐5; repeated every 3 weeks) versus a triplet regimen (three courses of docetaxel, 70 mg/m 2 day 1; cisplatin 70 mg/m 2 day 1; and 5‐ FU 750 mg/m 2 days 1‐5; repeated every 3 weeks) versus a chemoradiotherapy ( CRT ) regimen (radiotherapy of 41.4 Gy/23 fractions with two courses of cisplatin 75 mg/m 2 day 1 and 5‐ FU 1000 mg/m 2 days 1‐4; repeated every 4 weeks). Development of a multimodal strategy for neoadjuvant therapy is expected to receive the continuous focus of research in the hope of achieving better outcomes from treatment of patients with advanced thoracic esophageal cancer.